框架核酸编程的阿巴美尔-帕克利塔塞尔结合物作为针对三阴性乳腺癌的向疗法
Lin Li1, Pengyao Wei1, Tong Kong1
1Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Ningbo Cixi Institute of Biomedical Engineering, Ningbo Institute of Materials Technology and Engineering of Chinese Academy of Sciences, Ningbo, 315300, P. R. China. wangkaizhe@nimte.ac.cn.
Nanoscale horizons
|March 13, 2025
概括
研究人员开发了一种新型的阿巴美尔-帕克利塔塞尔结合物 (FAPC) 用于针对性三阴性乳腺癌 (TNBC) 化疗. 这种框架核酸平台精确地提供了帕克利塔塞尔,提高了在临床前模型中的疗效和降低毒性.
科学领域:
- 生物化学 生物化学
- 纳米技术纳米技术
- 在瘤学瘤学.
背景情况:
- 三重阴性乳腺癌 (TNBC) 由于其侵袭性和预后不佳而构成重大临床挑战.
- 目前的化疗,像帕克利塔塞尔,遭受非特异性分布,限制有效性和增加副作用.
- 开发有针对性的药物输送系统对于改善TNBC治疗结果至关重要.
研究的目的:
- 为针对性化疗设计精确结构的框架核酸编程的阿巴美尔-帕克利塔塞尔合物 (FAPC).
- 通过调节体间距来优化FAPC,以增强瘤细胞亲和力.
- 在TNBC的临床前模型中评估FAPC的抗瘤疗效和安全性.
主要方法:
- 制造一个框架核酸支架,准确定位AS1411的APTAMER.
- 优化阿普坦体间距 (19.04 nm) 以最大限度地提高FAPC对瘤细胞的亲和力.
- 在体外评估FAPC诱导的细胞毒性通过破坏actin重组.
- 在人体TNBC异种移植模型中对FAPC瘤向,疗效和毒性的体内评估.
主要成果:
- 优化的FAPC表现出对瘤细胞的增强亲和力,这种亲和力归因于特定的aptamer间距.
- 通过破坏actin重组,FAPC有效地诱导瘤细胞中的细胞毒性.
- AS1411修饰的FAPC在瘤部位表现出结构依赖的选择性药物积累.
- 在体内观察到抗瘤疗效的显著改善和全身毒性降低.
结论:
- 框架核酸编程的阿巴美尔-帕克利塔塞尔合物 (FAPC) 为向化疗提供了一个精确可编程的平台.
- 优化的FAPC证明了对三阴性乳腺癌的有效和更安全的治疗潜力.
- 这种方法推动了针对癌症治疗的纳米药物的开发.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K


